809 F. Supp. 2d 296
D. Del.2011Background
- Patent infringement action under Hatch-Waxman concerning Oracea®, a 40 mg daily doxycycline product for rosacea, with five patents asserted by Galderma and Mylan’s ANDA product at issue.
- Plaintiffs RF SUNY, NYU, GLI, GLLP, and Supernus sue Mylan; the court conducted a four-day bench trial in July 2011 and issued post-trial briefing.
- Oracea® features a 40 mg oral capsule with 30 mg IR and 10 mg DR beads; Mylan’s product mirrors this composition and is bioequivalent.
- The Ashley patents concern sub-antibacterial or near-antibiotic dosing for rosacea; the Amin patents concern NO/iNOS modulation by tetracyclines; the Chang patent covers a specific IR/DR 30:10 formulation with a 0.3–0.8 ng/mL trough range.
- The court held that Mylan infringes the Chang patent but not the Ashley or Amin patents; Amin patents were found invalid; preliminary injunction remained in place pending remedy briefing.
- Remedy phase scheduled; the injunction will remain in place while the court determines appropriate permanent relief.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Infringement of Ashley '267/'572 patents | Galderma: Mylan’s 40 mg daily dose infringes by not significantly inhibiting growth of microorganisms. | Mylan: in vivo data show significant growth inhibition; Label does not infringe. | Ashley patents not infringed. |
| Validity of Ashley patents (anticipation/obviousness) | Galderma: Feldman uses and prior art show no anticipation/obviousness. | Mylan: Feldman uses and six Gilchrest refs anticipate or render obvious. | Ashley patents not invalid; no clear and convincing anticipation or obviousness. |
| Infringement of Amin '395/'775 patents | Galderma asserts NO/iNOS mechanism and NO reduction prove infringement. | Mylan: no evidence that 40 mg daily doxycycline reduces NO/iNOS in vivo. | Amin patents not infringed. |
| Validity of Amin patents (anticipation) | Amin claims valid over prior art; NO/iNOS mechanism anticipated by prior references. | Mylan: prior art inherently anticipates; lack of enablement argued separately. | Amin patents invalid for inherent anticipation; enablement not reached. |
| Infringement of Chang '532 patent | Galderma: Mylan’s product meets 30 mg IR/10 mg DR with trough 0.3–0.8 µg/mL, infringing claims 4 and 18. | Mylan: not all data show 0.3–0.8 trough; however pivotal PK supports infringement for claims 4 and 18. | Chang patent infringed (claims 4 and 18). |
Key Cases Cited
- Dynacore Holdings Corp. v. U.S. Philips Corp., 363 F.3d 1263 (Fed. Cir. 2004) (indirect infringement requires direct infringement)
- Clock Spring, L.P. v. Wrapmaster, Inc., 560 F.3d 1317 (Fed. Cir. 2009) (public-use and on-sale considerations in anticipation)
- TypeRight Keyboard Corp. v. Microsoft Corp., 374 F.3d 1151 (Fed. Cir. 2004) (corroboration requirement for anticipation)
- Mars, Inc. v. Coin Acceptors, Inc., 527 F.3d 1359 (Fed. Cir. 2008) (damages and remedy considerations in patent cases)
- Microsoft Corp. v. i4i L.P., 131 S. Ct. 2238 (2011) (clear-and-convincing standard for invalidity)